CordenPharma, a CDMO, created a new Technology & Science Advisory Board (TSAB) with eight experts from academia and industry to provide strategic guidance and scientific expertise to drive the company’s continued growth and innovation.

By harnessing the knowledge and insights of renowned scientists and industry leaders, the company aims to enhance its capabilities in the efficient development and manufacturing of APIs, lipid excipients, drug products, and integrated supply to support the complex modalities of its broad pharmaceutical customer base.

CordenPharma’s TSAB brings together eight scientific experts from various disciplines, including chemistry, pharmacology, biotechnology, and regulatory affairs.

Their collective expertise will provide valuable insights into emerging trends, cutting-edge technologies, and regulatory advancements across all six CordenPharma technology platforms. This collaboration will further enable the CDMO to anticipate industry developments and ensure its readiness to meet the evolving needs of customers and their life-saving medicines.

The new board members include renowned experts in the fields of drug development, peptides, oligonucleotides, lipids, injectable lipid nanoparticles (LNPs), RNA drug delivery, highly potent oral solid dose (OSD), flow chemistry, and small molecules. While the board will initially look at science-focused areas, they will also explore bioinformatics, including AI and machine learning, in the future.

• José de Chastonay, Independent Consultant for Strategic M&A and Business Development (Portugal / Switzerland)
• Christian Oliver Kappe, Professor of Chemistry, University of Graz (Austria)
• Hiroshi Kikuchi, President of DDS Strategy Firm (Japan)
• Olivia Merkel, Professor and Chair of Drug Delivery, LMU Munich (Germany)
• Jean-Christophe Monbaliu, Professor of Organic Chemistry, Center for Integrated Technology and Organic Synthesis, University of Liège (Belgium)
• Christoph Rosenbohm, MBA, Chief Technology Officer (CTO), Aloop Therapeutics (Denmark)
• Roderich Süssmuth, Rudolf-Wiechert-Professor and Chair of Biological Chemistry, Technical University Berlin (Germany)
• Prof. Karl Wagner, Professor of Pharmaceutical Technology and Biopharmacy, University of Bonn (Germany)

Michael Quirmbach, CEO & President at CordenPharma, said: “CordenPharma is honored to have the opportunity to work with these distinguished scientific experts. We look forward to leveraging their renowned experience to continue driving innovation across our six technology platforms and delivering exceptional value to support the complex modalities of our pharmaceutical and biotech customers.”